Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background Disturbances of the fibrinolytic system that lead to decreased removal of fibrin deposits may be important risk factors for coronary thrombosis. There is as yet no consensus on the prognostic value of fibrinolytic parameters, which may be attributed in part to the choice of confounding variables controlled for. Methods and Results The ECAT study is a prospective multicenter study of 3043 patients with angina pectoris followed for 2 years. Baseline measurements included 10 fibrinolytic variables. The results were analyzed in relation to the subsequent incidence of myocardial infarction or sudden coronary death. They are presented before and after adjustment for clusters of confounding variables that are markers of different mechanisms: insulin resistance (body mass index, triglyceride, and HDL cholesterol), inflammation (fibrinogen and C-reactive protein), and endothelial cell damage (von Willebrand factor). An increased incidence of events was associated with higher baseline concentrations of tissue plasminogen activator (TPA) antigen ( P =.0002), plasminogen activator inhibitor-1 (PAI-1) activity ( P =.02), and PAI-1 antigen ( P =.001). The associations of PAI-1 activity and PAI-1 antigen with risk of events disappeared after adjustment for parameters reflecting insulin resistance but were not affected by other adjustments. TPA antigen was affected to a similar extent by adjustment for parameters reflecting insulin resistance, inflammation, or endothelial cell damage, but the risk association disappeared only after combined adjustments. Conclusions The prognostic role of PAI-1 in predicting coronary events is related principally to insulin resistance, whereas that of TPA antigen could be explained only by its relationship with different mechanisms, including insulin resistance, inflammation, and endothelial cell damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260506 · Cited by 3,725
Prevalence of Total Coronary Occlusion during the Early Hours of Transmural Myocardial Infarction
DeWood, M. A., Spores, J., Notske, R., Mouser, L. T., Burroughs, R., Golden, M. S., & Lang, H. T. (1980) · New England Journal of Medicine · doi:10.1056/nejm198010163031601 · Cited by 2,740
Thompson, S. G., Kienast, J., Pyke, S. D. M., Haverkate, F., & van de Loo, J. C. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321003 · Cited by 1,821
Self-citationThrombosis and Acute Coronary-Artery Lesions in Sudden Cardiac Ischemic Death
Davies, M. J., & Thomas, A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198405033101801 · Cited by 1,694
QUANTITATIVE METHODS IN THE REVIEW OF EPIDEMIOLOGIC LITERATURE1
GREENLAND, S. (1987) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036298 · Cited by 1,644
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., Faire, U., Dahlén, G., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Fibrinogen as a Cardiovascular Risk Factor: A Meta-Analysis and Review of the Literature
Ernst, E., & Resch, K. L. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-12-199306150-00008 · Cited by 990
Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome
Ferrannini, E., Haffner, S. M., Mitchell, B. D., & Stern, M. P. (1991) · Diabetologia · doi:10.1007/bf00403180 · Cited by 898
MEADE, T. (1993) · The Lancet · doi:10.1016/0140-6736(93)92062-x · Cited by 711
Cited by
Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961
Koenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,964
The Emergence of the Metabolic Syndrome with Menopause
Carr, M. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030242 · Cited by 1,449
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan, R. S. (2006) · Circulation · doi:10.1161/circulationaha.104.482570 · Cited by 1,212
Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Rosenson, R. S., & Tangney, C. C. (1998) · JAMA · doi:10.1001/jama.279.20.1643 · Cited by 954
Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease
Kohler, H. P., & Grant, P. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422406 · Cited by 806
Rost, N. S., Wolf, P. A., Kase, C. S., Kelly-Hayes, M., Silbershatz, H., Massaro, J. M., D'Agostino, R. B., Franzblau, C., & Wilson, P. W. F. (2001) · Stroke · doi:10.1161/hs1101.098151 · Cited by 801
Mitochondrial Dysfunction in Atherosclerosis
Madamanchi, N. R., & Runge, M. S. (2007) · Circulation Research · doi:10.1161/01.res.0000258450.44413.96 · Cited by 797
Is visceral obesity the cause of the metabolic syndrome?
Després, J. (2006) · Annals of Medicine · doi:10.1080/07853890500383895 · Cited by 651
Salpeter, S. R., Walsh, J. M. E., Ormiston, T. M., Greyber, E., Buckley, N. S., & Salpeter, E. E. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00545.x · Cited by 640
Thögersen, A. M., Jansson, J.-H., Boman, K., Nilsson, T. K., Weinehall, L., Huhtasaari, F., & Hallmans, G. (1998) · Circulation · doi:10.1161/01.cir.98.21.2241 · Cited by 602
HDL and arteriosclerosis: beyond reverse cholesterol transport
Nofer, J.-R., Kehrel, B., Fobker, M., Levkau, B., Assmann, G., & Eckardstein, A. V. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00651-7 · Cited by 595
Oddo, M., Schaller, M.-D., Feihl, F., Ribordy, V., & Liaudet, L. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000221922.08878.49 · Cited by 593
VAUGHAN, D. E. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01420.x · Cited by 507
Hepatic insulin resistance, metabolic syndrome and cardiovascular disease
Meshkani, R., & Adeli, K. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.05.018 · Cited by 458
Cesari, M., Pahor, M., & Incalzi, R. A. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00171.x · Cited by 448
Diabetes mellitus as a prothrombotic condition
Grant, P. J. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01824.x · Cited by 443
von Känel, R., Mills, P. J., Fainman, C., & Dimsdale, J. E. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200107000-00003 · Cited by 422
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences
Alessi, M.-C., & Juhan-Vague, I. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000242905.41404.68 · Cited by 390
Self-citationPAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events
Juhan-Vague, I., & Alessi, M. C. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657607 · Cited by 384
Self-citationNewby, D. E., Wright, R. A., Labinjoh, C., Ludlam, C. A., Fox, K. A. A., Boon, N. A., & Webb, D. J. (1999) · Circulation · doi:10.1161/01.cir.99.11.1411 · Cited by 382
Effects of Hormone-Replacement Therapy on Fibrinolysis in Postmenopausal Women
Koh, K. K., Mincemoyer, R., Bui, M. N., Csako, G., Pucino, F., Guetta, V., Waclawiw, M., & Cannon, R. O. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361002 · Cited by 373
Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk
Juhan-Vague, I., Alessi, M.-C., Mavri, A., & Morange, P. E. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00279.x · Cited by 371
Self-citationMeltzer, M. E., Lisman, T., de Groot, P. G., Meijers, J. C. M., le Cessie, S., Doggen, C. J. M., & Rosendaal, F. R. (2010) · Blood · doi:10.1182/blood-2010-02-267740 · Cited by 364
Scarabin, P.-Y., Alhenc-Gelas, M., Plu-Bureau, G., Taisne, P., Agher, R., & Aiach, M. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.11.3071 · Cited by 348
Alessi, M. C., Bastelica, D., Morange, P., Berthet, B., Leduc, I., Verdier, M., Geel, O., & Juhan-Vague, I. (2000) · Diabetes · doi:10.2337/diabetes.49.8.1374 · Cited by 344
Self-citationPleiotropic functions of plasminogen activator inhibitor-1
LIJNEN, H. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00827.x · Cited by 312
Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1
Skurk, T., & Hauner, H. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802778 · Cited by 297
Jager, A., van Hinsbergh, V. W. M., Kostense, P. J., Emeis, J. J., Yudkin, J. S., Nijpels, G., Dekker, J. M., Heine, R. J., Bouter, L. M., & Stehouwer, C. D. A. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.12.3071 · Cited by 288
The role of plaque rupture and thrombosis in coronary artery disease
Zaman, A. G., Helft, G., Worthley, S. G., & Badimon, J. J. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00479-7 · Cited by 280
McEntegart, A. (2001) · Rheumatology · doi:10.1093/rheumatology/40.6.640 · Cited by 273
The post-prandial state and cardiovascular disease: relevance to diabetes mellitus
Ceriello, A. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(200003/04)16:2<125::aid-dmrr90>3.0.co;2-4 · Cited by 264
Elkind, M. S. V., Tai, W., Coates, K., Paik, M. C., & Sacco, R. L. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2073 · Cited by 255
Obesity and Insulin Resistance: Epidemiologic, Metabolic, and Molecular Aspects
Després, J.-P., & Marette, A. (1999) · Insulin Resistance · doi:10.1007/978-1-59259-716-1_4 · Cited by 248
The Metabolic Syndrome and Inflammation
Sutherland, J. P., McKinley, B., & Eckel, R. H. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.82 · Cited by 243
YAMAMOTO, K., TAKESHITA, K., KOJIMA, T., TAKAMATSU, J., & SAITO, H. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.11.013 · Cited by 214
Effects of Lifestyle on Hemostasis, Fibrinolysis, and Platelet Reactivity: A Systematic Review
Lee, K. W., & Lip, G. Y. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.19.2368 · Cited by 217
Effects of lipids and lipoproteins on thrombosis and rheology
Rosenson, R. S., & Lowe, G. D. O. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00144-0 · Cited by 205
Eriksson, P., Nilsson, L., Karpe, F., & Hamsten, A. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.1.20 · Cited by 187
Adipose tissue and metabolic syndrome: too much, too little or neither
Grundy, S. M. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12519 · Cited by 187
Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes
Krysiak, R., Okopie??, B., & Herman, Z. S. (2003) · Drugs · doi:10.2165/00003495-200363170-00005 · Cited by 165
Novel Risk Factors for Atherosclerosis
Kullo, I. J., Gau, G. T., & Tajik, A. J. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.4.369 · Cited by 161
Landin-Wilhelmsen, K., Bryman, I., & Wilhelmsen, L. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7818 · Cited by 113
Janszky, I., Eriksson-Berg, M., Al-Khalili, F., Schenck-Gustafsson, K., & Nagy, E. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-10-0650 · Cited by 9
Metadata
- Authors
- Juhan-Vague, I., Pyke, S. D. M., Alessi, M. C., Jespersen, J., Haverkate, F., & Thompson, S. G.
- Venue
- Circulation
- Published
- 1996-11
- Volume
- 94
- Issue
- 9
- Pages
- 2057-2063
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1980840278
- Cited by
- 552
- References
- 45
- FWCI
- 19.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.